The ECHO model proved to be a useful tool to increase clinicians' self-effectiveness for care of patients with Hepatitis C in Argentina.

Abstract:

:The ECHO model was developed to expand access to medical care for populations with HCV infection in underserved areas. We aimed to compare HCV treatment outcomes in community-based clinics with the Austral University Hospital (AUH) and to assess improvement in physician knowledge and skills. In October 2015, we established an HCV ECHO clinic at the AUH in Buenos Aires. To evaluate the impact of this programme, we conducted a prospective cohort study comparing treatment for HCV infection at the AUH with healthcare providers from different Argentinean provinces. A survey evaluating skills and competence in HCV care was administered, and results were compared. The primary endpoint was sustained virologic response (SVR) and under direct-acting antivirals. Since the implementation of ECHO clinics, a total of 25 physicians participated in at least one session (median 10.0; IQR 3.0-18.0). SVR rates (n = 437 patients) were 94.2% (95% CI 90.4-96.8) in patients treated at AUH clinic (n = 227/242) and 96.4% (95% CI 92.7-98.5) in those treated at ECHO sites (n = 188/195), with a nonsignificant difference between sites, 2.2% SVR difference (95% CI -0.24-0.06; P = 0.4). We also found a significant improvement in all the evaluated skills and abilities. Replicating the ECHO model helped to improve participants' skills in the management of HCV achieving similar SVR rates. ECHO model was demonstrated to be an effective intervention able to multiply and expand HCV treatment, a critical barrier to access to care that needs to be solved if we are committed with WHO goals to eliminate HCV by 2030.

journal_name

J Viral Hepat

authors

Mendizabal M,Ridruejo E,Ceballos S,Sixto M,Billordo A,Gadea C,Mengarelli S,Alonso C,Palazzo A,De María L,Bruno A,Perez D,Piñero F,Deltrozzo V,Mendoza C,Figueroa S,Manero E,Villa M,Barreyro F,Moreno V,Vilar J,Mur

doi

10.1111/jvh.13172

subject

Has Abstract

pub_date

2019-11-01 00:00:00

pages

1284-1292

issue

11

eissn

1352-0504

issn

1365-2893

journal_volume

26

pub_type

杂志文章
  • Hepatitis C virus genotype 4 with normal transaminases: histological changes, schistosomiasis and response to treatment.

    abstract::Among individuals with chronic hepatitis C virus (HCV) infection, approximately 30% of patients show persistently normal alanine aminotransferase (PNALT). Individuals with PNALT have been historically excluded from antiviral treatment. However, some studies have reported sudden worsening of disease in patients with PN...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01403.x

    authors: Derbala MF,Amer AM,Almohanadi M,John A,Amin A,John A,Sharma M,Alkaabi SR,Al Dweik NZ,Pasic F,Yaqoob R,Butt MT,Shebl FM

    更新日期:2011-07-01 00:00:00

  • Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss.

    abstract::Viral load reduction facilitates recovery of antiviral T-cell responses. Dynamic alterations in intrahepatic viraemia clearance and immune cell reactivity during the early phase of nucleoside analogue (NA) therapy and the impact of these changes on HBeAg seroconversion are unknown. Fifteen HBeAg-positive chronic hepat...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12261

    authors: Zheng Q,Zhu YY,Chen J,Liu YR,You J,Dong J,Zeng DW,Gao LY,Chen LH,Jiang JJ

    更新日期:2014-12-01 00:00:00

  • Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection.

    abstract::Serological and biochemical studies indicate that acute HBV infection is resolved in the context of an efficient cell-mediated immune (CMI) response, whereas, chronic infection is characterized by weak to undetectable CMI responses and relatively efficient humoral immunity. Because humoral immunity and CMI are regulat...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.1997.tb00180.x

    authors: Milich DR

    更新日期:1997-01-01 00:00:00

  • The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.

    abstract::Triple therapy using boceprevir or telaprevir remains the reference treatment for genotype 1 chronic hepatitis C in countries where new interferon-free regimens have not yet become available. Antiviral treatment is highly required in cirrhotic patients, but they represent a difficult-to-treat population. We aimed to d...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12433

    authors: Boursier J,Ducancelle A,Vergniol J,Veillon P,Moal V,Dufour C,Bronowicki JP,Larrey D,Hézode C,Zoulim F,Fontaine H,Canva V,Poynard T,Allam S,De Lédinghen V,ANRS CO20 CUPIC Study Group.

    更新日期:2015-12-01 00:00:00

  • Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.

    abstract::Little is known about engagement and retention in care of people diagnosed with chronic hepatitis C (HCV) in England. Establishing a cascade of care informs targeted interventions for improving case finding, referral, treatment uptake and retention in care. Using data from the sentinel surveillance of blood-borne viru...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12844

    authors: Simmons R,Ireland G,Irving W,Hickman M,Sabin C,Ijaz S,Ramsay M,Lattimore S,Mandal S

    更新日期:2018-05-01 00:00:00

  • Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.

    abstract::Patients with chronic hepatitis B (HBsAg-positive) are at risk of viral reactivation if rituximab is administered without antiviral treatment, a potentially fatal complication of treatment. Patients with so-called 'resolved hepatitis B virus infection' (HBsAg-negative/cAb-positive) may also be at risk. We performed a ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/jvh.12402

    authors: Mozessohn L,Chan KK,Feld JJ,Hicks LK

    更新日期:2015-10-01 00:00:00

  • Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project.

    abstract::Italy is one of the countries on track with the WHO's agenda to eliminate hepatitis C virus (HCV) by 2030. Healthcare facilities play a crucial role in seeking patients who are infected but have not yet been treated. We assessed the effectiveness of a recall strategy, named 'Telepass' project, for patients exposed to ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13465

    authors: Ponziani FR,Santopaolo F,Siciliano M,De Belvis AG,Tortora A,Mora V,Fanali C,Morsella A,Balducci F,Vetrugno G,D'Alfonso ME,Cambieri A,Cauda R,Bellantone R,Sanguinetti M,Pompili M,Gasbarrini A

    更新日期:2021-01-09 00:00:00

  • Modelling the decline and future of hepatitis A transmission in Australia.

    abstract::Hepatitis A incidence has declined in most countries through a combination of prevention measures, augmented through the use of a highly effective vaccine. In Australia, the proportion of the population susceptible to hepatitis A infection has declined over time due to high rates of opportunistic vaccination as well a...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13018

    authors: Jayasundara D,Hui BB,Regan DG,Heywood AE,MacIntyre CR,Wood JG

    更新日期:2019-01-01 00:00:00

  • Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation.

    abstract::Antiviral therapy has been shown to improve the prognosis of hepatitis B virus (HBV) DNA-positive hepatocellular carcinoma (HCC) after radical treatment, but antiviral treatments require further optimization. This study aimed to evaluate the efficacies of different antiviral strategies with HCC patients after hepatect...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13236

    authors: Qi W,Zhang Q,Xu Y,Wang X,Yu F,Zhang Y,Zhao P,Guo H,Zhou C,Wang Z,Sun Y,Liu L,Xuan W,Wang J

    更新日期:2020-04-01 00:00:00

  • Frequent delayed spontaneous seroclearance of hepatitis B virus after incident HBV infection among adult high-risk groups.

    abstract::High rates (~25%) of developing chronic hepatitis B virus (HBV) infection (hepatitis B surface antigen (HBsAg)-positive for > 6 months following infection) have been observed in people who use drugs (PWUD) and men who have sex with men (MSM). We aimed to estimate the frequency of delayed HBsAg seroclearance, along wit...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13205

    authors: van Santen DK,Boyd A,Bruisten S,Sonder GJ,Prins M,van Houdt R

    更新日期:2020-01-01 00:00:00

  • Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.

    abstract::The aims of the present study were to assess initial virological response (IVR) to adefovir (ADV) treatment for chronic hepatitis B, to identify patients with suboptimal response and to determine the incidence of ADV-resistant mutants. All patients treated with ADV for at least 12 months were evaluated for virological...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2007.00966.x

    authors: Gallego A,Sheldon J,García-Samaniego J,Margall N,Romero M,Hornillos P,Soriano V,Enrĺquez J

    更新日期:2008-05-01 00:00:00

  • Anti-envelope antibody responses in highly exposed seronegative individuals may be associated with protection from HCV infection.

    abstract::In rare cases, individuals with a history of long-term injecting drug use remain seronegative and aviraemic, despite prolonged and likely repeated exposure to Hepatitis C virus (HCV) through high-risk behaviour. We describe anti-HCV Envelope (E) antibody responses in a prospective cohort of carefully defined highly ex...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13339

    authors: Mina M,Underwood A,Eltahla A,Wu BR,Walker MR,Bull RA,Lloyd AR

    更新日期:2020-10-01 00:00:00

  • Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients.

    abstract::To assess the impact of sequential therapy with adefovir dipivoxil (ADV) and pegylated interferon alfa-2a (PEG-IFN) on virological (serum HBV-DNA) and serological (serum HBsAg) response in 20 consecutive HBeAg-negative patients. Patients received ADV for 20 weeks, then ADV and PEG-IFN for 4 weeks and lastly PEG-IFN fo...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2010.01332.x

    authors: Moucari R,Boyer N,Ripault MP,Castelnau C,Mackiewicz V,Dauvergne A,Valla D,Vidaud M,Chanoine MH,Marcellin P

    更新日期:2011-08-01 00:00:00

  • Increased intrahepatic and circulating levels of endoglin, a TGF-beta1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis.

    abstract::Endoglin, a transforming growth factor (TGF)-beta1 co-receptor, has been associated with renal and cutaneous fibrosis, as overexpression of this protein has been observed in biopsies from patients with glomerulosclerosis and scleroderma, respectively. Our aim was to evaluate whether endoglin may be associated with hep...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00733.x

    authors: Clemente M,Núñez O,Lorente R,Rincón D,Matilla A,Salcedo M,Catalina MV,Ripoll C,Iacono OL,Bañares R,Clemente G,García-Monzón C

    更新日期:2006-09-01 00:00:00

  • Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.

    abstract::It is unknown whether dynamic changes of liver stiffness measurement (LSM) can predict the reversibility of fibrosis. Therefore, we evaluated the utility of LSM changes in predicting histological changes of fibrosis in patients with chronic hepatitis B (CHB) on antiviral therapy. In a prospective cohort of CHB patient...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13058

    authors: Kong Y,Sun Y,Zhou J,Wu X,Chen Y,Piao H,Lu L,Ding H,Nan Y,Jiang W,Xu Y,Xie W,Li H,Feng B,Shi G,Chen G,Li H,Zheng H,Cheng J,Wang T,Liu H,Lv F,Shao C,Mao Y,Sun J,Chen T,Han T,Han Y,Wang L,Ou X,Zha

    更新日期:2019-05-01 00:00:00

  • Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother-to-child transmission of hepatitis B virus.

    abstract::Women with chronic hepatitis B should maintain nucleotide analogue treatment to prevent disease progression during pregnancy. The aim of this study was to prospectively evaluate the efficacy and safety of telbivudine used throughout pregnancy for preventing hepatitis B virus (HBV) mother-to-child transmission (MTCT). ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12788

    authors: Yi W,Li MH,Xie Y,Wu J,Hu YH,Zhang D,Zhang Y,Cao WH

    更新日期:2017-11-01 00:00:00

  • Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.

    abstract::The aim of this study was to assess the efficacy and safety of two protocols for retreatment of a cohort of Egyptian patients with chronic hepatitis C (CHC) who relapsed after NS5A inhibitor-based therapy. We conducted a prospective cohort study to assess the safety and efficacy of 12 weeks' retreatment with either co...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13349

    authors: Yousif MM,Ahmed H,Elsadek HM,Shendi AM,Gouda TM,Elsayed IA,Gendia MA,Magdy MM,Lbrahim NF,Sadek AMEM,Zaki AM,Shafeik H,Zahran MH

    更新日期:2020-11-01 00:00:00

  • Therapy of chronic hepatitis B: current challenges and opportunities.

    abstract::Better understanding of hepatitis B virus (HBV) replication, natural history and the immunopathogenesis of chronic hepatitis B, together with the introduction of effective agents with different mechanisms of action are the basis for better therapeutic strategies against chronic hepatitis B. Among currently available d...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.2002.00388.x

    authors: Liaw YF

    更新日期:2002-11-01 00:00:00

  • Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy.

    abstract::To study the correlation between total Hepatitis C virus (HCV) Core antigen (Ag) and HCV-RNA, and to assess the proficiency of HCV Core Ag testing in monitoring and predicting virologic response during and after pegylated interferon (PEG-IFN) and ribavirin combination therapy. A total of 307 samples from treated and u...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2003.00430.x

    authors: Maynard M,Pradat P,Berthillon P,Picchio G,Voirin N,Martinot M,Marcellin P,Trepo C

    更新日期:2003-07-01 00:00:00

  • Treatment of chronic hepatitis C virus infection in patients with cirrhosis.

    abstract::Chronic hepatitis C virus (HCV) infection eventually leads to cirrhosis in 20-30% of patients and to hepatocellular carcinoma (HCC) in 1-5% of patients. Rates of sustained virological response with standard interferon-alpha (IFN-alpha) are low in patients without cirrhosis (generally < 20%) and are even lower in those...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.2000.00229.x

    authors: Zeuzem S

    更新日期:2000-09-01 00:00:00

  • Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.

    abstract::Several direct-acting antivirals (DAAs) have been approved for the treatment of chronic hepatitis C virus (HCV) infections, opening the door to highly effective interferon-free treatment regimens. Resistance-associated substitutions (RASs) have been reported both in treatment-naïve patients and following treatment wit...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12615

    authors: Eltahla AA,Rodrigo C,Betz-Stablein B,Grebely J,Applegate T,Luciani F,Schinkel J,Dore GJ,Page K,Bruneau J,Morris MD,Cox AL,Kim AY,Shoukry NH,Lauer GM,Maher L,Hellard M,Prins M,Lloyd AR,Bull RA,InC3 Study Group.

    更新日期:2017-01-01 00:00:00

  • Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.

    abstract::This study estimated latent classes (ie, unobserved subgroups in a population) of people who use drugs in Vancouver, Canada, and examined how these classes relate to phylogenetic clustering of hepatitis C virus (HCV) infection. HCV antibody-positive people who use drugs from two cohorts in Vancouver, Canada (1996-2012...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12758

    authors: Jacka B,Bray BC,Applegate TL,Marshall BDL,Lima VD,Hayashi K,DeBeck K,Raghwani J,Harrigan PR,Krajden M,Montaner JSG,Grebely J Senior

    更新日期:2018-01-01 00:00:00

  • Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry.

    abstract::The impact of direct-acting antiviral (DAA) therapies on fibrosis regression remains uncertain. In the current study, we prospectively evaluated dynamics of liver stiffness by transient elastography (TE) in patients with chronic HCV infection receiving DAA-based treatment. Patients (260) were enrolled in the German He...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13280

    authors: Knop V,Mauss S,Goeser T,Geier A,Zimmermann T,Herzer K,Postel N,Friedrich-Rust M,Hofmann WP,German Hepatitis C-Registry.

    更新日期:2020-07-01 00:00:00

  • Morbidity and mortality of recurrent hepatitis C infection after orthotopic liver transplantation.

    abstract::Through molecular virological testing it is now clear that HCV reinfection of the allograft is virtually universal in liver transplant recipients. Although histopathological recurrence of hepatitis C occurs in the majority of patients, it is absent in a substantial minority. To date, no prognostic factors, other than ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.1997.tb00172.x

    authors: Vierling JM,Villamil FG,Rojter SE,Camacho KB,Goldman DE

    更新日期:1997-01-01 00:00:00

  • Methamphetamine enhances Hepatitis C virus replication in human hepatocytes.

    abstract::Very little is known about the interactions between hepatitis C virus (HCV) and methamphetamine, which is a highly abused psychostimulant and a known risk factor for human immunodeficiency virus (HIV)/HCV infection. This study examined whether methamphetamine has the ability to inhibit innate immunity in the host cell...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2007.00940.x

    authors: Ye L,Peng JS,Wang X,Wang YJ,Luo GX,Ho WZ

    更新日期:2008-04-01 00:00:00

  • Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy.

    abstract::For hepatitis B virus (HBV)-related chronic infection under treatment by nucleos(t)ide analogues (NUCs), HBsAg clearance is the ultimate therapeutic goal but very infrequent. We investigated how HBV envelope protein variability could lead to differential HBsAg clearance on NUCs. For 12 HBV genotype D patients receivin...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12498

    authors: Velay A,Jeulin H,Eschlimann M,Malvé B,Goehringer F,Bensenane M,Frippiat JP,Abraham P,Ismail AM,Murray JM,Combet C,Zoulim F,Bronowicki JP,Schvoerer E

    更新日期:2016-05-01 00:00:00

  • DNA methylation patterns of peroxisome proliferator-activated receptor gamma gene associated with liver fibrosis and inflammation in chronic hepatitis B.

    abstract::Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor that regulates gene expression of inflammatory mediators in liver injury. Hepatitis B virus (HBV) suppresses the PPAR gamma-mediated transactivation in liver cancerous cell lines. However, the role of PPAR gamma in patients with chroni...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12048

    authors: Zhao Q,Fan YC,Zhao J,Gao S,Zhao ZH,Wang K

    更新日期:2013-06-01 00:00:00

  • The molecular basis of hepatitis B e antigen (HBeAg)-negative infections.

    abstract::Hepatitis B e antigen (HBeAg)-negative infections are an unusual form of chronic hepatitis B virus (HBV) infection in which viral replication and liver damage persist despite antibodies against HBeAg. This form of HBV may be associated with fulminant hepatitis. The molecular basis for an HBeAg-minus phenotype has been...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.1997.00101.x

    authors: Miyakawa Y,Okamoto H,Mayumi M

    更新日期:1997-01-01 00:00:00

  • Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection.

    abstract::In this study, a comprehensive methodology for modelling the hepatitis C virus (HCV) epidemic is proposed to predict the future disease burden and assess whether the recent decline in the incidence of HCV may affect the future occurrence of cirrhosis and hepatocellular carcinoma (HCC) cases. Using the prevalence of HC...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2004.00517.x

    authors: Sypsa V,Touloumi G,Tassopoulos NC,Ketikoglou I,Vafiadis I,Hatzis G,Tsantoulas D,Akriviadis E,Delladetsima J,Demonakou M,Hatzakis A

    更新日期:2004-07-01 00:00:00

  • Somatic hypermutation and mRNA expression levels of the BCL-6 gene in patients with hepatitis C virus-associated lymphoproliferative diseases.

    abstract::Chronic hepatitis C virus (HCV) infection leads to mixed cryoglobulinaemia (MC) and B-cell non-Hodgkin lymphoma (B-NHL). Aberrant somatic hypermutation and deregulation of the oncogene BCL-6 is associated with lymphomagenesis. Recently, HCV was shown to induce BCL-6 mutations in vitro. The BCL-6 gene (area B) was clon...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00833.x

    authors: Hofmann WP,Fernandez B,Herrmann E,Welsch C,Mihm U,Kronenberger B,Feldmann G,Spengler U,Zeuzem S,Sarrazin C

    更新日期:2007-07-01 00:00:00